PEX2

Across TCGA pan-cancer cohorts, PEX2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PEX2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PEX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PEX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.684	0.901	.012	27	view →
LUAD	DFS	Median	All	0.465	0.869	<.001	25	view →
LSCC	DFS	Quartile	All	0.294	1.000	.006	13	view →
HNSC	DFS	Quartile	All	0.571	0.931	.016	7	view →
CCRCC	OS	Tertile	All	0.648	1.000	.036	6	view →
UCEC	OS	Median	III,IV	0.802	0.539	.049	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PEX2–PDAC (OS)

Open the PDAC breakdown →